A citation-based method for searching scientific literature

Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell, William T Cefalu, Paul Strumph. Diabetes Care 2015
Times Cited: 121



T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
Times Cited: 102




List of shared articles



Times cited

Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Hailan Zou, Lili Liu, Jia Guo, Hongjuan Wang, Siyun Liu, Yixuan Xing, Chao Deng, Yang Xiao, Zhiguang Zhou. J Diabetes Investig 2021
1


A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.
Curtis K Johnston, Rena J Eudy-Byrne, Ahmed Elmokadem, Valerie Nock, Jan Marquard, Nima Soleymanlou, Matthew M Riggs, Karl-Heinz Liesenfeld. Pharmaceutics 2021
0

Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.
Ane Bayona Cebada, Lía Nattero-Chávez, Sara Alonso Díaz, Héctor F Escobar-Morreale, Manuel Luque-Ramírez. Diabetes Technol Ther 2020
1

Evaluation of the safety of sodium-glucose co-transporter-2 inhibitors for treating patients with type 1 diabetes.
Weihao Wang, Lina Zhang, Xiaobei Pei, Qi Pan, Lixin Guo. Diabetes Obes Metab 2020
2

Adjunct therapies in treatment of type 1 diabetes.
Itivrita Goyal, Alamgir Sattar, Megan Johnson, Paresh Dandona. J Diabetes 2020
3




Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes.
Diana Isaacs, Stephanie Yager, Marcie Parker, Lauren Wolfe, Jennifer Luxenburg, Sanela Lekic. Ann Pharmacother 2019
3


Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
38

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Baruch Itzhak, Nebojsa Lalic, Dario Rahelic, Jan Skrha, Paul Valensi, Antonio Ceriello. Cardiovasc Diabetol 2019
17


What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
18

Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes.
Sara E Lingow, Sandra D Burke, Amie D Brooks, Pat S Rafferty. Diabetes Spectr 2019
0


Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
11

Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
Rozalina G McCoy, Hayley J Dykhoff, Lindsey Sangaralingham, Joseph S Ross, Pinar Karaca-Mandic, Victor M Montori, Nilay D Shah. Diabetes Technol Ther 2019
29

Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice.
Caroline Daems, Sophie Welsch, Hasnae Boughaleb, Juliette Vanderroost, Annie Robert, Etienne Sokal, Philippe A Lysy. J Diabetes Res 2019
7




Adjunctive therapy for glucose control in patients with type 1 diabetes.
Kira Harris, Cassie Boland, Lisa Meade, Dawn Battise. Diabetes Metab Syndr Obes 2018
10

Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Thomas Danne, Torben Biester, Olga Kordonouri. Diabetes Technol Ther 2018
19

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
95

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
77

Non-insulin pharmacological therapies for treating type 1 diabetes.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad, Jens Juul Holst. Expert Opin Pharmacother 2018
6

Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes.
Mustafa Tosur, Maria J Redondo, Sarah K Lyons. Curr Diab Rep 2018
5

SGLT inhibitor adjunct therapy in type 1 diabetes.
Rory J McCrimmon, Robert R Henry. Diabetologia 2018
40

Development of SGLT1 and SGLT2 inhibitors.
Timo Rieg, Volker Vallon. Diabetologia 2018
78

Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Harriet Warnes, Rebecca Helliwell, Sam Matthew Pearson, Ramzi A Ajjan. Diabetes Ther 2018
11


Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
Susanne Famulla, Thomas R Pieber, Jens Eilbracht, Dietmar Neubacher, Nima Soleymanlou, Hans J Woerle, Uli C Broedl, Stefan Kaspers. Diabetes Technol Ther 2017
31

The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.
Jiao Chen, Fang Fan, J Y Wang, Yang Long, C L Gao, R C Stanton, Yong Xu. Sci Rep 2017
45



Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
190

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
147

Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?
Ewa Otto-Buczkowska, Natalia Jainta. Int J Endocrinol Metab 2017
4